A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome - 22/06/22
, Gyula Talosi, MD 2, Annalisa Piccinno, Msc 3, Virginia Maria Ginocchio, MD 3, Gyorgy Balla, MD 4, Anna Lavizzari, MD 5, Zbynek Stranak, MD 6, Eloisa Gitto, MD 7, Stefano Martinelli, MD 8, Richard Plavka, MD 9, Barbara Krolak-Olejnik, MD 10, Gianluca Lista, MD 11, Francesca Spedicato, MSc 3, Giorgia Ciurlia, MSc 3, Debora Santoro, Msc 3, David Sweet, MD 12on behalf of the
CURONEB Study Group∗
Abstract |
Objective |
To investigate the efficacy and safety of nebulized poractant alfa (at 200 and 400 mg/kg doses) delivered in combination with nasal continuous positive airway pressure compared with nasal continuous positive airway pressure alone in premature infants with diagnosed respiratory distress syndrome.
Study design |
This randomized, controlled, multinational study was conducted in infants at 280/7 to 326/7 weeks of gestation. The primary outcome was the incidence of respiratory failure in the first 72 hours of life, defined as needing endotracheal surfactant and/or mechanical ventilation owing to prespecified criteria. Secondary outcomes included the time to respiratory failure in the first 72 hours, duration of ventilation, mortality, incidence of bronchopulmonary dysplasia, and major associated neonatal comorbidities. In addition, the safety and tolerability of the treatments were assessed reporting the number and percentage of infants with treatment-emergent adverse events and adverse drug reactions during nebulization.
Results |
In total, 129 infants were randomized. No significant differences were observed for the primary outcome: 24 (57%), 20 (49%), and 25 (58%) infants received endotracheal surfactant and/or mechanical ventilation within 72 hours in the poractant alfa 200 mg/kg, poractant alfa 400 mg/kg, and nasal continuous positive airway pressure groups, respectively. Similarly, secondary respiratory outcomes did not differ among groups. Enrollment was halted early owing to a change in the benefit-risk balance of the intervention. Nebulized poractant alfa was well-tolerated and safe, and no serious adverse events were related to the study treatment.
Conclusions |
The intervention did not decrease the likelihood of respiratory failure within the first 72 hours of life.
Trial Registration |
clinicaltrials.gov: NCT03235986
Le texte complet de cet article est disponible en PDF.Keywords : respiratory distress syndrome, nebulized surfactant, poractant alfa, vibrating-membrane nebulizer, investigational eFlow Neos nebulizer, aerosol delivery
Abbreviations : AUC, FiO2, CPAP, nCPAP, RDS, SpO2, TEAE
Plan
| The present study was funded by Chiesi Farmaceutici S.p.A., manufacturer of poractant alfa, the surfactant preparation used in this trial. Chiesi Farmaceutici S.p.A. provided the eFlow Neos nebulizer and the surfactant for the trial. The funder was involved in the design, monitoring, supervision, report writing, and in the decision to submit the manuscript for publication. G.L. received honoraria from Chiesi for educational lectures. A.P., V.G., F.S., G.C., and D.S. are employees of Chiesi Farmaceutici S.p.A.. The other authors declare no conflicts of interest. |
Vol 246
P. 40 - juillet 2022 Retour au numéro
Article précédent
- Perinatal Inflammatory Biomarkers and Respiratory Disease in Preterm Infants
- Joseph M. Collaco, Sharon A. McGrath-Morrow, Megan Griffiths, Raul Chavez-Valdez, Charlamaine Parkinson, Jie Zhu, Frances J. Northington, Ernest M. Graham, Allen D. Everett
- Brain Volumes and Abnormalities in Adults Born Preterm at Very Low Birth Weight
- Juho Kuula, Juha Martola, Antti Hakkarainen, Katri Räikkönen, Sauli Savolainen, Eero Salli, Petteri Hovi, Johan Björkqvist, Eero Kajantie, Nina Lundbom
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?